Skip to main content
SpringerLink
Log in

Predictors of neoadjuvant chemotherapy for triple-negative breast cancer: a meta-analysis with 723 cases

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

Neoadjuvant chemotherapy (NAC) was increasingly used as a systemic therapy for triple-negative breast cancer (TNBC). The pathological complete response (PCR) rates of neoadjuvant chemotherapy in TNBC were higher than other types of breast cancer with fluctuate data. Predictors to identify which subgroup TNBC was more likely to achieve PCR in neoadjuvant chemotherapy would give us some hints on how to improve outcomes of TNBC patients. The meta-analysis was conducted to contrast the prognostic function of some clinicopathological parameters in the PCR rates of neoadjuvant chemotherapy for TNBC.

Methods

Studies were selected from the PubMed database. The relevant parameters to PCR rates in TNBC group were recorded. Review Manager and MIX were used to estimate prognostic function of some biological markers and clinicopathological parameters in PCR rates of TNBC.

Results

The analysis included 6 studies with 723 patients, the aggregate PCR rate was 27.9% in TNBC group. The association of lymph nodes metastasis, Ki-67 expression, p53 expression and CK5/6 expression with PCR rate of TNBC was investigated in the analysis, and the odds ratios were 0.50, 9.87, 1.17 and 0.53 respectively.

Conclusion

This meta-analysis demonstrated that Ki-67 expression and lymph nodes metastasis were predictors of PCR rate for TNBC in neoadjuvant chemotherapy, while p53 and CK5/6 expression could not be confirmed for the prognostic function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol, 2010, 33: 637–645.

    Article  PubMed  Google Scholar 

  2. Shi XB, Wang L. Treatment for triple-negative breast cancer. Chinese-German J Clin Oncol, 2012, 11: 539–543.

    Article  CAS  Google Scholar 

  3. Yagata H, Kajiura Y, Yamauchi H. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer, 2011, 18: 165–173.

    Article  PubMed  Google Scholar 

  4. Yagata H, Kajiura Y, Yamauchi H, et al. Current strategy for triplenegative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer, 2011, 18: 165–173.

    Article  PubMed  Google Scholar 

  5. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 2008, 26: 1275–1281.

    Article  PubMed  Google Scholar 

  6. Bernsdorf M, Ingvar C, Jörgensen L, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat, 2011, 126: 463–470.

    Article  PubMed  CAS  Google Scholar 

  7. Iwata H, Sato N, Masuda N, et al. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol, 2011, 41: 867–875.

    Article  PubMed  Google Scholar 

  8. De Laurentiisa M, Cianniellob D, Caputob R, et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev, 2010, 36: S80–S86.

    Article  Google Scholar 

  9. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basallike phenotype:a possible precursor to invasive basal-like breast cancer. Mod Pathol, 2006, 19: 617–621.

    Article  PubMed  CAS  Google Scholar 

  10. Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol, 2008, 19: 1261–1265.

    Article  PubMed  Google Scholar 

  11. Darb-Esfahani S, Loibl S, Müller BM, et al. Identification of biologybased breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res, 2009, 11: R69.

    Article  PubMed  Google Scholar 

  12. Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat, 2012, 132: 793–805.

    Article  PubMed  CAS  Google Scholar 

  13. Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triplenegative breast cancer patients. Cancer Chemother Pharmacol, 2011, 67: 911–917.

    Article  PubMed  CAS  Google Scholar 

  14. Li XR, Liu M, Zhang YJ, et al. CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast can-cer patients. Med Oncol, 2011, 28: S129–S134.

    Article  PubMed  Google Scholar 

  15. Keam B, Im SA, Lee KH, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res, 2011, 13: R22.

    Article  PubMed  Google Scholar 

  16. Colleoni M, Viale G, Zahrieh D, et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol, 2008, 19: 465–472.

    Article  PubMed  CAS  Google Scholar 

  17. Guarneri V, Barbieri E, Piacentini F, et al. Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis. Int J Biol Markers, 2010, 25: 104–111.

    PubMed  Google Scholar 

  18. Nakagawa M, Bando Y, Nagao T, et al. Expression of p53, Ki-67, Ecadherin, N-cadherin and TOP2A in triple-negative breast cancer. Anticancer Res, 2011, 31: 2389–2393.

    PubMed  CAS  Google Scholar 

  19. Andre F, Pusztai L. Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. Pharm Res, 2006, 23: 1951–1958.

    Article  PubMed  CAS  Google Scholar 

  20. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple negative Breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res, 2009, 15: 2301–2310.

    Article  Google Scholar 

  21. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer-current status and future directions. Ann Oncol, 2009, 20: 1913–1927.

    Article  PubMed  CAS  Google Scholar 

  22. Bonnefoi H, Diebold-Berger S, Therasse P, et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol, 2003, 14: 406–413.

    Article  PubMed  CAS  Google Scholar 

  23. Rocca A, Viale G, Gelber RD, et al. Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: Correlation with p63 expression. Cancer Chemother Pharmacol, 2008, 61: 965–971.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, The General Hospital of Shenyang Military Region, Shenyang, 110840, China

    Guojing Zhang, Long Xu, Zhaozhe Liu & Xiaodong Xie

  2. Molecular Biology Laboratory of Traditional Chinese Medicine, The Basic Medical College of Liaoning University of Traditional Chinese Medicine, Shenyang, 110032, China

    Wanqing Xie

Authors
  1. Guojing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wanqing Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Long Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhaozhe Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaodong Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wanqing Xie.

Additional information

Supported by a grant from the Science & Technology Supporting Foundation of Liaoning Province (No. 20102060).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, G., Xie, W., Xu, L. et al. Predictors of neoadjuvant chemotherapy for triple-negative breast cancer: a meta-analysis with 723 cases. Chin. -Ger. J. Clin. Oncol. 12, 15–19 (2013). https://doi.org/10.1007/s10330-012-1104-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-012-1104-8

Key words

Search

Navigation